Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.

Coler RN, Bhatia A, Maisonneuve JF, Probst P, Barth B, Ovendale P, Fang H, Alderson M, Lobet Y, Cohen J, Mettens P, Reed SG.

FEMS Immunol Med Microbiol. 2009 Mar;55(2):258-70. doi: 10.1111/j.1574-695X.2008.00527.x.

2.

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, Prieels JP, Abalos RM, Dubois MC, Cohen J, Mettens P, Lobet Y.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2301-6. doi: 10.1073/pnas.0712077106. Epub 2009 Feb 2. Erratum in: Proc Natl Acad Sci U S A.2009 May 5;106(18):7678. Dalemans, Wilifred [corrected to Dalemans, Wilfried].

3.

Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning.

Coler RN, Dillon DC, Skeiky YA, Kahn M, Orme IM, Lobet Y, Reed SG, Alderson MR.

Vaccine. 2009 Jan 7;27(2):223-33. doi: 10.1016/j.vaccine.2008.10.056. Epub 2008 Nov 8.

4.

Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.

Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W.

Am J Trop Med Hyg. 2008 Jul;79(1):115-22.

PMID:
18606774
5.

Tuberculosis vaccine development; from mouse to man.

Reed S, Lobet Y.

Microbes Infect. 2005 May;7(5-6):922-31. Epub 2005 Apr 14. Review.

PMID:
15935717
6.

Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41.

Skeiky YA, Alderson MR, Ovendale PJ, Lobet Y, Dalemans W, Orme IM, Reed SG, Campos-Neto A.

Vaccine. 2005 Jun 10;23(30):3937-45. Epub 2005 Mar 30.

PMID:
15917115
7.

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, Huygen K, Ottenhoff TH, Franken KL, Andersen P, Doherty TM, Kaufmann SH, Grode L, Seiler P, Martin C, Gicquel B, Cole ST, Brodin P, Pym AS, Dalemans W, Cohen J, Lobet Y, Goonetilleke N, McShane H, Hill A, Parish T, Smith D, Stoker NG, Lowrie DB, Källenius G, Svenson S, Pawlowski A, Blake K, Marsh PD.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):29-38. Epub 2005 Jan 20.

PMID:
15687025
8.

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, Basaraba RJ, Izzo AA, Lasco TM, Chapman PL, Reed SG, Orme IM.

Infect Immun. 2004 Nov;72(11):6622-32.

9.

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein.

Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, Reed SG.

J Immunol. 2004 Jun 15;172(12):7618-28.

10.

Early detection of Borrelia burgdorferi sensu lato infection in Balb/c mice by co-feeding Ixodes ricinus ticks.

Hua CM, Cheminade Y, Perret JL, Weynants V, Lobet Y, Gern L.

Int J Med Microbiol. 2003 Dec;293(6):421-6.

PMID:
14760973
11.

Prospects for a better vaccine against tuberculosis.

Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YA.

Tuberculosis (Edinb). 2003;83(1-3):213-9. Review.

PMID:
12758214
12.

Assessment of the nasopharyngeal bacterial flora of rhesus macaques: moraxella, Neisseria, haemophilus, and other genera.

Bowers LC, Purcell JE, Plauché GB, Denoel PA, Lobet Y, Philipp MT.

J Clin Microbiol. 2002 Nov;40(11):4340-2.

13.

Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.

Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA.

Nat Med. 2002 Aug;8(8):878-84. Epub 2002 Jul 1.

PMID:
12091878
14.

Expression, refolding and crystallization of the OpcA invasin from Neisseria meningitidis.

Prince SM, Feron C, Janssens D, Lobet Y, Achtman M, Kusecek B, Bullough PA, Derrick JP.

Acta Crystallogr D Biol Crystallogr. 2001 Aug;57(Pt 8):1164-6. Epub 2001 Jul 23.

PMID:
11468407
15.

Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.

Pal U, Montgomery RR, Lusitani D, Voet P, Weynants V, Malawista SE, Lobet Y, Fikrig E.

J Immunol. 2001 Jun 15;166(12):7398-403.

16.

Transmission of Borrelia garinii OspA serotype 4 to BALB/c mice by Ixodes ricinus ticks collected in the field.

Hu CM, Wilske B, Fingerle V, Lobet Y, Gern L.

J Clin Microbiol. 2001 Mar;39(3):1169-71.

17.

Developing a nontypeable Haemophilus influenzae (NTHi) vaccine.

Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, Lobet Y.

Vaccine. 2000 Dec 8;19 Suppl 1:S108-15. Review.

PMID:
11163473
18.

Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL.

Liang FT, Aberer E, Cinco M, Gern L, Hu CM, Lobet YN, Ruscio M, Voet PE Jr, Weynants VE, Philipp MT.

J Infect Dis. 2000 Nov;182(5):1455-62. Epub 2000 Oct 9.

PMID:
11023468
19.

Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A.

Pal U, de Silva AM, Montgomery RR, Fish D, Anguita J, Anderson JF, Lobet Y, Fikrig E.

J Clin Invest. 2000 Aug;106(4):561-9.

21.

An effective vaccine against Lyme disease.

Crooy P, Lobet Y.

J Biotechnol. 2000 Jan 21;76(2-3):261-3. No abstract available.

PMID:
10656342
22.

Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.

Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, Lobet Y.

Infect Immun. 1999 Jun;67(6):2746-62. Erratum in: Infect Immun 1999 Oct;67(10):5545.

23.

The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey.

Philipp MT, Lobet Y, Bohm RP Jr, Roberts ED, Dennis VA, Gu Y, Lowrie RC Jr, Desmons P, Duray PH, England JD, Hauser P, Piesman J, Xu K.

Vaccine. 1997 Dec;15(17-18):1872-87.

PMID:
9413097
25.

Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.

Golde WT, Piesman J, Dolan MC, Kramer M, Hauser P, Lobet Y, Capiau C, Desmons P, Voet P, Dearwester D, Frantz JC.

Infect Immun. 1997 Mar;65(3):882-9.

26.

Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults.

Van Hoecke C, Comberbach M, De Grave D, Desmons P, Fu D, Hauser P, Lebacq E, Lobet Y, Voet P.

Vaccine. 1996 Dec;14(17-18):1620-6.

PMID:
9032890
27.

Efficacy of human Lyme disease vaccine formulations in a mouse model.

Telford SR 3rd, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA, Fikrig E.

J Infect Dis. 1995 May;171(5):1368-70.

PMID:
7751719
28.

The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.

Golde WT, Burkot TR, Piesman J, Dolan MC, Capiau C, Hauser P, Dequesne G, Lobet Y.

Vaccine. 1995 Apr;13(5):435-41.

PMID:
7639011
29.

Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients.

Demaerschalck I, Ben Messaoud A, De Kesel M, Hoyois B, Lobet Y, Hoet P, Bigaignon G, Bollen A, Godfroid E.

J Clin Microbiol. 1995 Mar;33(3):602-8.

30.

Vaccination against Lyme disease caused by diverse Borrelia burgdorferi.

Fikrig E, Telford SR 3rd, Wallich R, Chen M, Lobet Y, Matuschka FR, Kimsey RB, Kantor FS, Barthold SW, Spielman A, Flavell RA.

J Exp Med. 1995 Jan 1;181(1):215-21.

32.

Tick transmission of Borrelia burgdorferi to inbred strains of mice induces an antibody response to P39 but not to outer surface protein A.

Golde WT, Kappel KJ, Dequesne G, Feron C, Plainchamp D, Capiau C, Lobet Y.

Infect Immun. 1994 Jun;62(6):2625-7. Erratum in: Infect Immun 1995 Mar;63(3):1146.

33.

Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.

Gern L, Rais O, Capiau C, Hauser P, Lobet Y, Simoen E, Voet P, Pêtre J.

Immunol Lett. 1994 Mar;39(3):249-58.

PMID:
8034340
34.

Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin.

Lobet Y, Feron C, Dequesne G, Simoen E, Hauser P, Locht C.

J Exp Med. 1993 Jan 1;177(1):79-87.

35.

Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, fla, HSP60, and HSP70 gene probes.

Wallich R, Helmes C, Schaible UE, Lobet Y, Moter SE, Kramer MD, Simon MM.

Infect Immun. 1992 Nov;60(11):4856-66.

37.
38.

Effects of mutations on enzyme activity and immunoreactivity of the S1 subunit of pertussis toxin.

Lobet Y, Cieplak W Jr, Smith SG, Keith JM.

Infect Immun. 1989 Nov;57(11):3660-2.

39.
40.

Frame-shift mutation in the lacZ gene of certain commercially available pUC18 plasmids.

Lobet Y, Peacock MG, Cieplak W Jr.

Nucleic Acids Res. 1989 Jun 26;17(12):4897. No abstract available.

41.

Methylated proteins and amino acids in the ribosomes of Saccharomyces cerevisiae.

Lhoest J, Lobet Y, Costers E, Colson C.

Eur J Biochem. 1984 Jun 15;141(3):585-90.

Supplemental Content

Support Center